# A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

> **NCT01098240** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 297 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** CP-601,927
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01098240
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06-14
- **Primary completion:** 2011-09-12
- **Final completion:** 2011-09-12
- **Target enrollment:** 297 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098240, "A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01098240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*